Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Three patients died in Novartis trials of its CD19-directed CAR-T treatment following a dangerous immune system response, and a similar therapy from Bristol Myers Squibb has also been put on hold to review safety issues ...